#Pathology AI Market

[delvenservices]

Pathology AI Market is Booming Worldwide by 2030

Pathology AI (Artificial Intelligence) Market research report provides an analytical measurement of the main challenges faced by the business currently and in the upcoming years. This Pathology AI Market report also offers a profound overview of product specification, technology, product type and production analysis by taking into account most important factors such as revenue, cost, and gross margin. Proficient capabilities and excellent resources in research, data collection, development, consulting, evaluation, compliance and regulatory services come together to generate this world-class market research report. This Pathology AI (Artificial Intelligence) Market report is especially designed by keeping in mind the customer requirements which will ultimately assist them in boosting their return on investment (ROI).

Pathology AI (Artificial Intelligence) Market Competitive Landscape:

General Electric Co. (GE Healthcare)

Koninklijke Philips N.V

F. Hoffmann-La Roche Ltd

Hologic, Inc

Akoya Biosciences, Inc

Aiforia

Indica Labs Inc

OptraScan

Ibex Medical Analytics Ltd.

Mindpeak GmbH

Tribun Health

Siemens Healthineers

Zebra Medical Vision, Inc.

Riverain Technologies

IDx Technologies Inc.

NovaSignal Corporation

Vuno, Inc.

Aidoc

Neural Analytics

Imagen Technologies

Digital Diagnostics, Inc.

GE Healthcare

AliveCor Inc.

Proscia Inc

PathAl, Inc.

Tempus Labs, Inc.

Pathology AI (Artificial Intelligence) Market, by Component (Software, Services), Neural network (CNN, GAN, RNN), Application (Drug Discovery, Diagnosis, Prognosis, Workflow, Education), End User (Pharma, Biotech, Hospital Labs, Research) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The global Pathology AI (Artificial Intelligence) market size was estimated at USD 23.4 million in 2023 and is projected to reach USD 66.53 billion in 2030 at a CAGR of 16.1% during the forecast period 2023–2030.

Pathology AI (Artificial Intelligence) Market analysis report figures out market landscape, brand awareness, latest trends, possible future issues, industry trends and customer behaviour so that the business can stand high in the crowd. It includes an extensive research on the current conditions of the industry, potential of the market in the present and the future prospects from various angles. This market report comprises of data that can be pretty essential when it comes to dominating the market or making a mark in the Pharmaceutical industry as a new emergent. To bestow clients with the best results, Pathology AI Market research document is produced by using integrated approaches and latest technology.

Make an Inquiry Before Buying at: https://www.delvens.com/Inquire-before-buying/pathology-ai-market

Scope of the Pathology AI (Artificial Intelligence) Market Report:

The Pathology AI (Artificial Intelligence) Market is segmented into various segments such as component, neural network, application, end user and region:

Based on component

Software

Scanners

Based on the Neural network

CNN

GAN

RNN

Based on the Application

Drug Discovery

Diagnosis

Prognosis

Workflow

Education

Based on End User

Pharma

Biotech

Hospital Labs

Research

Based on region

Asia Pacific

North America

Europe

South America

Middle East & Africa

Pathology AI (Artificial Intelligence) Market Regional Analysis:

North America to Dominate the Market

North America is estimated to account for the largest market share during the forecast period. In North America, there is growing investments and reforms to modernize the pathology infrastructure in the region and the increasing adoption of digital pathology solutions.

Moreover, the expansion of healthcare infrastructure and growing market availability of advanced AI technologies.

Pathology AI (Artificial Intelligence) Market Reasons to Acquire:

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.

Gain authentic and granular data access for the Pathology AI (Artificial Intelligence) Market to understand the trends and the factors involved in changing market situations.

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Direct Purchase of the Pathology AI (Artificial Intelligence) Market Research Report at: https://www.delvens.com/checkout/pathology-ai-market

Explore Related Reports:

Pendred Syndrome (PS) Market

Multiple Sclerosis (MS) Market

Plastic Surgery and Integumentary System Market

Pain Relief Gel Market

Antibody Drug Conjugates (ADC) Market

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44–20–8638–5055

SALES@DELVENS.COM

[trendtrackershq]

𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐓𝐫𝐞𝐧𝐝𝐬 𝐚𝐧𝐝 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭

𝐒𝐞𝐜𝐮𝐫𝐞 𝐚 𝐅𝐑𝐄𝐄 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.nextmsc.com/digital-pathology-market/request-sample

As we continue to witness advancements in healthcare technology, the 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 is poised for remarkable growth. With the integration of AI, machine learning, and digital imaging, the field of pathology is undergoing a transformative journey.

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬:

𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐚𝐧𝐝 𝐀𝐜𝐜𝐮𝐫𝐚𝐜𝐲: Digital pathology solutions streamline workflows, enabling pathologists to analyze slides more efficiently and accurately. This leads to faster diagnosis and treatment decisions, ultimately improving patient outcomes.

𝐑𝐞𝐦𝐨𝐭𝐞 𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲: The ability to access digital slides remotely allows for collaboration among pathologists across different locations. This facilitates knowledge sharing and enhances diagnostic accuracy through collective expertise.

𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐀𝐈: Artificial intelligence algorithms are revolutionizing pathology by assisting in tasks such as image analysis, pattern recognition, and predictive diagnostics. This synergy between human expertise and AI capabilities is driving innovation in disease detection and classification.

𝐓𝐞𝐥𝐞𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲: Telepathology services are expanding accessibility to pathology expertise in underserved regions, bridging the gap between patients and specialists. This remote consultation model enhances healthcare delivery, particularly in remote or rural areas.

𝐌𝐚𝐣𝐨𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Lucrative growth opportunities make the digital pathology market extremely competitive. Some of the major players in the market are Danaher Corporation, 3DHISTECH - The Digital Pathology Company, Glencoe Software, Indica Labs, Nikon, PerkinElmer, Roche, Visiopharm, and more.

𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.nextmsc.com/report/digital-pathology-market

𝐋𝐞𝐭'𝐬 𝐄𝐦𝐛𝐫𝐚𝐜𝐞 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞:

As we navigate the evolving landscape of healthcare, embracing digital pathology technologies is crucial for enhancing diagnostic accuracy, improving patient care, and advancing medical research. Together, let's harness the power of digital innovation to revolutionize the way we approach pathology and ultimately, transform healthcare for the better.

[mostlysignssomeportents]

What the fuck is a PBM?

TOMORROW (Sept 24), I'll be speaking IN PERSON at the BOSTON PUBLIC LIBRARY!

Terminal-stage capitalism owes its long senescence to its many defensive mechanisms, and it's only by defeating these that we can put it out of its misery. "The Shield of Boringness" is one of the necrocapitalist's most effective defenses, so it behooves us to attack it head-on.

The Shield of Boringness is Dana Claire's extremely useful term for anything so dull that you simply can't hold any conception of it in your mind for any length of time. In the finance sector, they call this "MEGO," which stands for "My Eyes Glaze Over," a term of art for financial arrangements made so performatively complex that only the most exquisitely melted brain-geniuses can hope to unravel their spaghetti logic. The rest of us are meant to simply heft those thick, dense prospectuses in two hands, shrug, and assume, "a pile of shit this big must have a pony under it."

MEGO and its Shield of Boringness are key to all of terminal-stage capitalism's stupidest scams. Cloaking obvious swindles in a lot of complex language and Byzantine payment schemes can make them seem respectable just long enough for the scammers to relieve you of all your inconvenient cash and assets, though, eventually, you're bound to notice that something is missing.

If you spent the years leading up to the Great Financial Crisis baffled by "CDOs," "synthetic CDOs," "ARMs" and other swindler nonsense, you experienced the Shield of Boringness. If you bet your house and/or your retirement savings on these things, you experienced MEGO. If, after the bubble popped, you finally came to understand that these "exotic financial instruments" were just scams, you experienced Stein's Law ("anything that can't go forever eventually stops"). If today you no longer remember what a CDO is, you are once again experiencing the Shield of Boringness.

As bad as 2008 was, it wasn't even close to the end of terminal stage capitalism. The market has soldiered on, with complex swindles like carbon offset trading, metaverse, cryptocurrency, financialized solar installation, and (of course) AI. In addition to these new swindles, we're still playing the hits, finding new ways to make the worst scams of the 2000s even worse.

That brings me to the American health industry, and the absurdly complex, ridiculously corrupt Pharmacy Benefit Managers (PBMs), a pathology that has only metastasized since 2008.

On at least 20 separate occasions, I have taken it upon myself to figure out how the PBM swindle works, and nevertheless, every time they come up, I have to go back and figure it out again, because PBMs have the most powerful Shield of Boringness out of the whole Monster Manual of terminal-stage capitalism's trash mobs.

PBMs are back in the news because the FTC is now suing the largest of these for their role in ripping off diabetics with sky-high insulin prices. This has kicked off a fresh round of "what the fuck is a PBM, anyway?" explainers of extremely variable quality. Unsurprisingly, the best of these comes from Matt Stoller:

https://www.thebignewsletter.com/p/monopoly-round-up-lina-khan-pharma

Stoller starts by pointing out that Americans have a proud tradition of getting phucked by pharma companies. As far back as the 1950s, Tennessee Senator Estes Kefauver was holding hearings on the scams that pharma companies were using to ensure that Americans paid more for their pills than virtually anyone else in the world.

But since the 2010s, Americans have found themselves paying eye-popping, sky-high, ridiculous drug prices. Eli Lilly's Humolog insulin sold for $21 in 1999; by 2017, the price was $274 – a 1,200% increase! This isn't your grampa's price gouging!

Where do these absurd prices come from? The story starts in the 2000s, when the GW Bush administration encouraged health insurers to create "high deductible" plans, where patients were expected to pay out of pocket for receiving care, until they hit a multi-thousand-dollar threshold, and then their insurance would kick in. Along with "co-pays" and other junk fees, these deductibles were called "cost sharing," and they were sold as a way to prevent the "abuse" of the health care system.

The economists who crafted terminal-stage capitalism's intellectual rationalizations claimed the reason Americans paid so much more for health care than their socialized-medicine using cousins in the rest of the world had nothing to do with the fact that America treats health as a source of profits, while the rest of the world treats health as a human right.

No, the actual root of America's health industry's problems was the moral defects of Americans. Because insured Americans could just go see the doctor whenever they felt like it, they had no incentive to minimize their use of the system. Any time one of these unhinged hypochondriacs got a little sniffle, they could treat themselves to a doctor's visit, enjoying those waiting-room magazines and the pleasure of arranging a sick day with HR, without bearing any of the true costs:

https://pluralistic.net/2021/06/27/the-doctrine-of-moral-hazard/

"Cost sharing" was supposed to create "skin in the game" for every insured American, creating a little pain-point that stung you every time you thought about treating yourself to a luxurious doctor's visit. Now, these payments bit hardest on the poorest workers, because if you're making minimum wage, at $10 co-pay hurts a lot more than it does if you're making six figures. What's more, VPs and the C-suite were offered "gold-plated" plans with low/no deductibles or co-pays, because executives understand the value of a dollar in the way that mere working slobs can't ever hope to comprehend. They can be trusted to only use the doctor when it's truly warranted.

So now you have these high-deductible plans creeping into every workplace. Then along comes Obama and the Affordable Care Act, a compromise that maintains health care as a for-profit enterprise (still not a human right!) but seeks to create universal coverage by requiring every American to buy a plan, requiring insurers to offer plans to every American, and uses public money to subsidize the for-profit health industry to glue it together.

Predictably, the cheapest insurance offered on the Obamacare exchanges – and ultimately, by employers – had sky-high deductibles and co-pays. That way, insurers could pocket a fat public subsidy, offer an "insurance" plan that was cheap enough for even the most marginally employed people to afford, but still offer no coverage until their customers had spent thousands of dollars out-of-pocket in a given year.

That's the background: GWB created high-deductible plans, Obama supercharged them. Keep that in your mind as we go through the MEGO procedures of the PBM sector.

Your insurer has a list of drugs they'll cover, called the "formulary." The formulary also specifies how much the insurance company is willing to pay your pharmacist for these drugs. Creating the formulary and paying pharmacies for dispensing drugs is a lot of tedious work, and insurance outsources this to third parties, called – wait for it – Pharmacy Benefits Managers.

The prices in the formulary the PBM prepares for your insurance company are called the "list prices." These are meant to represent the "sticker price" of the drug, what a pharmacist would charge you if you wandered in off the street with no insurance, but somehow in possession of a valid prescription.

But, as Stoller writes, these "list prices" aren't actually ever charged to anyone. The list price is like the "full price" on the pricetags at a discount furniture place where everything is always "on sale" at 50% off – and whose semi-disposable sofas and balsa-wood dining room chairs are never actually sold at full price.

One theoretical advantage of a PBM is that it can get lower prices because it bargains for all the people in a given insurer's plan. If you're the pharma giant Sanofi and you want your Lantus insulin to be available to any of the people who must use OptumRX's formulary, you have to convince OptumRX to include you in that formulary.

OptumRX – like all PBMs – demands "rebates" from pharma companies if they want to be included in the formulary. On its face, this is similar to the practices of, say, NICE – the UK agency that bargains for medicine on behalf of the NHS, which also bargains with pharma companies for access to everyone in the UK and gets very good deals as a result.

But OptumRX doesn't bargain for a lower list price. They bargain for a bigger rebate. That means that the "price" is still very high, but OptumRX ends up paying a tiny fraction of it, thanks to that rebate. In the OptumRX formulary, Lantus insulin lists for $403. But Sanofi, who make Lantus, rebate $339 of that to OptumRX, leaving just $64 for Lantus.

Here's where the scam hits. Your insurer charges you a deductible based on the list price – $404 – not on the $64 that OptumRX actually pays for your insulin. If you're in a high-deductible plan and you haven't met your cap yet, you're going to pay $404 for your insulin, even though the actual price for it is $64.

Now, you'd think that your insurer would put a stop to this. They chose the PBM, the PBM is ripping off their customers, so it's their job to smack the PBM around and make it cut this shit out. So why would the insurers tolerate this nonsense?

Here's why: the PBMs are divisions of the big health insurance companies. Unitedhealth owns OptumRx; Aetna owns Caremark, and Cigna owns Expressscripts. So it's not the PBM that's ripping you off, it's your own insurance company. They're not just making you pay for drugs that you're supposedly covered for – they're pocketing the deductible you pay for those drugs.

Now, there's one more entity with power over the PBM that you'd hope would step in on your behalf: your boss. After all, your employer is the entity that actually chooses the insurer and negotiates with them on your behalf. Your boss is in the driver's seat; you're just along for the ride.

It would be pretty funny if the answer to this was that the health insurance company bought your employer, too, and so your boss, the PBM and the insurer were all the same guy, busily swapping hats, paying for a call center full of tormented drones who each have three phones on their desks: one labeled "insurer"; the second, "PBM" and the final one "HR."

But no, the insurers haven't bought out the company you work for (yet). Rather, they've bought off your boss – they're sharing kickbacks with your employer for all the deductibles and co-pays you're being suckered into paying. There's so much money (your money) sloshing around in the PBM scamoverse that anytime someone might get in the way of you being ripped off, they just get cut in for a share of the loot.

That is how the PBM scam works: they're fronts for health insurers who exploit the existence of high-deductible plans in order to get huge kickbacks from pharma makers, and massive fees from you. They split the loot with your boss, whose payout goes up when you get screwed harder.

But wait, there's more! After all, Big Pharma isn't some kind of easily pushed-around weakling. They're big. Why don't they push back against these massive rebates? Because they can afford to pay bribes and smaller companies making cheaper drugs can't. Whether it's a little biotech upstart with a cheaper molecule, or a generics maker who's producing drugs at a fraction of the list price, they just don't have the giant cash reserves it takes to buy their way into the PBMs' formularies. Doubtless, the Big Pharma companies would prefer to pay smaller kickbacks, but from Big Pharma's perspective, the optimum amount of bribes extracted by a PBM isn't zero – far from it. For Big Pharma, the optimal number is one cent higher than "the maximum amount of bribes that a smaller company can afford."

The purpose of a system is what it does. The PBM system makes sure that Americans only have access to the most expensive drugs, and that they pay the highest possible prices for them, and this enriches both insurance companies and employers, while protecting the Big Pharma cartel from upstarts.

Which is why the FTC is suing the PBMs for price-fixing. As Stoller points out, they're using their powers under Section 5 of the FTC Act here, which allows them to shut down "unfair methods of competition":

https://pluralistic.net/2023/01/10/the-courage-to-govern/#whos-in-charge

The case will be adjudicated by an administrative law judge, in a process that's much faster than a federal court case. Once the FTC proves that the PBM scam is illegal when applied to insulin, they'll have a much easier time attacking the scam when it comes to every other drug (the insulin scam has just about run its course, with federally mandated $35 insulin coming online, just as a generation of post-insulin diabetes treatments hit the market).

Obviously the PBMs aren't taking this lying down. Cigna/Expressscripts has actually sued the FTC for libel over the market study it conducted, in which the agency described in pitiless, factual detail how Cigna was ripping us all off. The case is being fought by a low-level Reagan-era monster named Rick Rule, whom Stoller characterizes as a guy who "hangs around in bars and picks up lonely multi-national corporations" (!!).

The libel claim is a nonstarter, but it's still wild. It's like one of those movies where they want to show you how bad the cockroaches are, so there's a bit where the exterminator shows up and the roaches form a chorus line and do a kind of Busby Berkeley number:

https://www.46brooklyn.com/news/2024-09-20-the-carlton-report

So here we are: the FTC has set out to euthanize some rentiers, ridding the world of a layer of useless economic middlemen whose sole reason for existing is to make pharmaceuticals as expensive as possible, by colluding with the pharma cartel, the insurance cartel and your boss. This conspiracy exists in plain sight, hidden by the Shield of Boringness. If I've done my job, you now understand how this MEGO scam works – and if you forget all that ten minutes later (as is likely, given the nature of MEGO), that's OK: just remember that this thing is a giant fucking scam, and if you ever need to refresh yourself on the details, you can always re-read this post.

The paperback edition of The Lost Cause, my nationally bestselling, hopeful solarpunk novel is out this month!

If you'd like an essay-formatted version of this post to read or share, here's a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2024/09/23/shield-of-boringness/#some-men-rob-you-with-a-fountain-pen

Image: Flying Logos (modified) https://commons.wikimedia.org/wiki/File:Over_$1,000,000_dollars_in_USD_$100_bill_stacks.png

CC BY-SA 4.0 https://creativecommons.org/licenses/by-sa/4.0/deed.en

[global-research-report]

Pathology Laboratories Market Insights: Innovations and Opportunities in Diagnostic Testing

The global pathology laboratories market size is estimated to reach USD 612.22 billion by 2030, registering a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the industry include increasing life expectancy, the development of healthcare infrastructure in developing nations, favoring reimbursement, and rising demand for routine medical check-ups.

In addition, the advancement of technology is altering the dynamics of diagnosis. Innovative technologies have made Point of Care Testing(POCT) devices portable and improved sampling techniques, making diagnostic services more accessible and efficient. Several advancements are expected to transform the industry by steering patient care through quality, speed, efficiency, and scalability. The healthcare system is progressively emphasizing the importance of pathological & diagnostic labs in becoming a greater clinical decision-making engine, assisting physicians in making inferences and diagnosing as well as monitoring patients more quickly and accurately.

The COVID-19 pandemic has resulted in higher demand for pathology/diagnostic labs as the testing for COVID-19 was necessary during the pandemic. The rapid rise of COVID-19 infections has resulted in increased funding and testing, which has boosted the overall market growth. For instance, the (NIH) National Institutes of Health in the United States announced in September 2020 that it would grant USD 129.3 million in funding to nine organizations including, Maxim Biomedical Inc., MatMaCorp, MicroGEM International, & others, for scaling-up manufacturing assistance to a new set of COVID-19 testing technologies as component of its initiative to boost diagnostics in the region.

Pathology Laboratories Market Report Highlights

Based on type, hospital-based diagnostic labs dominated the market during the year 2024. This can be attributed to the advanced tests available at hospitals, making them the only best solution for complex diagnosis

Based on the end use, physician referrals dominated the market in 2024. Walk-in and corporate clients are expected to witness lucrative growth due to increased self-awareness for monitoring health and wellness among individuals

S. is expected to have a high demand for the diagnosis of cardiovascular health as a result of the most prominent disease in the U.S.

Europe is expected to have a significant CAGR during the forecast period. Denmark has the highest prevalence of cancer globally in terms of cancer prevalence as per the World Cancer Research Fund International

The market is witnessing multiple collaborations in recent times with the key players aiming at adding value to their services & expanding their research. For Instance, in July 2022, Unilabs announced a partnership with Subtle Medical, to be the first diagnostic company to adopt their AI-based MRI technology for high-quality & quick MRI. The solution will be first launched in Sweden.

Pathology Laboratories Market Segmentation

Grand View Research has segmented the global pathology laboratories market on the basis of type, testing services, end-use, and region:

Pathology Laboratories Type Outlook (Revenue, USD Million, 2018 - 2030)

Hospital-based

Standalone Labs

Diagnostic Chains

Pathology Laboratories Testing Services Outlook (Revenue, USD Million, 2018 - 2030)

General Physiological & Clinical Tests

Imaging & Radiology Tests

Esoteric Tests

COVID-19 Tests

Pathology Laboratories End User Outlook (Revenue, USD Million, 2018 - 2030)

Physician Referrals

Walk-ins

Corporate

Pathology Laboratories Region Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East & Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players

Quest Diagnostics Incorporated

Eurofins Scientific

Laboratory Corporation of America Holdings

Exact Sciences Laboratories LLC

Spectra Laboratories

SYNLAB International GmbH

Sonic Healthcare Limited

Lal Path Labs

Metropolis Healthcare

Kingmed Diagnostics

Healius Limited

Centro de Diagnósticos

Falco Holdings

Unilabs

Order a free sample PDF of the Pathology Laboratories Market Intelligence Study, published by Grand View Research.

[lovelypol]

Pathology’s Digital Leap: Solutions Market to Soar to $6.3B by 2034

Digital Pathology Solutions Market is rapidly evolving, driving a revolution in how pathology workflows are digitized and managed. Key technologies such as digital imaging, image analysis software, and data management systems are enhancing diagnostic accuracy and efficiency, fostering a shift toward integrated healthcare solutions. With telepathology, healthcare professionals can collaborate remotely, improving access to specialized consultations and supporting personalized medicine and research.

To Request Sample Report : https://www.globalinsightservices.com/request-sample/?id=GIS10931 &utm_source=SnehaPatil&utm_medium=Article

Whole slide imaging takes the lead in the market, offering high-resolution digitization and enabling detailed analysis of pathology slides. This is closely followed by image analysis informatics, powered by advanced AI algorithms, which help improve diagnostic accuracy. The hardware segment, particularly scanners and storage systems, plays a pivotal role in supporting the growing demand for reliable data management. In 2023, approximately 320 million slides were analyzed globally, and the market is expected to reach 580 million slides by 2033.

Regionally, North America leads with a dominant market share, fueled by robust investments in digital healthcare infrastructure and regulatory support. Europe follows closely, especially as AI integration in precision medicine gains momentum. The Asia-Pacific region is emerging as a lucrative market, driven by growing healthcare expenditures and modernization efforts in countries like China and India.

Key players in the market, including Leica Biosystems, Philips Healthcare, and Roche Diagnostics, continue to innovate to stay ahead. Regulatory standards such as those from the FDA and European Medicines Agency ensure data security and interoperability. Looking ahead, the market is projected to grow at a 15% annual rate, with cloud-based solutions and AI integration driving further advancements.

#DigitalPathology #AIinHealthcare #Telepathology #WholeSlideImaging #DiseaseDiagnosis #MedicalInnovation #PathologySolutions #PrecisionMedicine #HealthTech #MedicalResearch #RemoteConsultations #Telemedicine #CloudSolutions #HealthcareDigitization #Biotech

[jcmarchi]

Jeff Elton, CEO at ConcertAI – Interview Series

New Post has been published on https://thedigitalinsider.com/jeff-elton-ceo-at-concertai-interview-series/

Jeff Elton, CEO at ConcertAI – Interview Series

Jeff Elton, Ph.D., is CEO of ConcertAI, an AI SaaS solutions company providing research solutions and patient-centric solutions for life sciences innovators and the world’s leading providers.  ConcertAI is focused on accelerating and improving the precision of retrospective and prospective clinical studies using provider EMRs, LISs, and PACSs systems as the source for all study data.  It is a long-term partner partner with the American Society of Clinical Oncology and its CancerLinQ program, US FDA, NCI Health Equity initiatives, and almost 100 healthcare providers across the US.

Prior to ConcertAI, Jeff was Managing Director, Accenture Strategy/Patient Health; Global Chief Operating Officer and SVP Strategy at Novartis Institutes of BioMedical Research, Inc.; and partner at McKinsey & Company.  He is also a founding board member and senior advisor to several early-stage companies. Jeff is currently a board member of the Massachusetts Biotechnology Council. He is the co-author of the widely cited book, Healthcare Disrupted (Wiley, 2016).  Jeff has a Ph.D. and M.B.A. from The University of Chicago.

As the founding CEO of ConcertAI, can you share your vision for the company at its inception? How has that vision evolved since 2018?

We started with the idea that improved patient outcomes come from deep and actionable insights. Gaining those insights requires data completeness, data scale, data representativeness and advanced AI intelligence. So, we created a Data-as-a-Service and AI Software-as-a-Service company. We targeted AI that allows inferencing and prediction. This included predicting events to avoid, such as patients’ non-adherence to their therapy or discontinuation of care because of a lack of positive response, which informed when clinical trials might be the next option.

Our vision has remained steadfast, and we continue to expect more out of our solutions. With the latest generation of LLMs, agentic AI and other generative AI solutions, we can operate at scale (and almost in real-time—something we did not expect or anticipate in 2018). With partners like NVIDIA, we can advance our solutions to perform better than expected, recognize limitations and unique characteristics, and move at the pace of the entire market’s innovations—the journey so far has been extraordinarily productive and exhilarating.

We have opened up previously unimaginable performance in clinical trial automation solutions, automating the placement of patients on evidence-based clinical pathways, advanced workflows in radiological interpretation, and the use of digital twins as a decision-enhancing tool for care and research.

Today, we serve almost 50 biopharma innovators and 2,000 healthcare providers—so while not at quite the scale of the entire market, we are the broadest-reaching AI solutions for oncology in the industry.

What inspired you to focus on oncology and hematology datasets specifically, and how did you see ConcertAI making a difference in these fields?

The United States started the “War on Cancer” in 1971 with the National Cancer Act. This catalyzed large-scale government funding, which generated insights into the mutations that drive cancers, new modalities for therapies, expanded National Cancer Institute-designated treatment centers, and more. Under the Obama administration, funding increased again by $10 billion in electronic stimulus going to the NIH and, in turn, to the NCI. Under Biden, the Cancer Moonshot 2.0 program was launched in 2022, again catalyzing an entirely new generation of research and seed funding investment for academic, community, and private-public partnerships.

I give this history because few diseases or areas of healthcare have the level of data: genomic, transcriptomic, digital pathology, digital radiology, detailed electronic medical records, etc., and the level of research that contextualizes these data with validated insights through rigorous, multi-center, peer-review studies. As further evidence, the American Society of Clinical Oncology annual meeting is the largest medical meeting in the world, with the greatest number of new publications, posters and abstracts of any scientific forum on any topic.

So, if you are going to be data and AI-centric, there are few better areas to advance solutions with confidence and at scale than oncology. ConcertAI has the largest collection of research-grade data of anyone in the world. It includes hundreds of peer-reviewed publications enabled by that data, significant evidence resulting from those publications changing how patients are treated and assuring the most positive possible outcomes, and now AI SaaS technologies that are integral to the processes of care and research that bring the power of that data and evidence to bear at all points and for all decisions along a patient’s care journey. What is really important here is that we don’t do this unilaterally. It is done transparently with our healthcare provider and biopharma innovator partners to engender the greatest confidence and use. So, we are evolving toward real-time, advanced, AI intelligence-enabled decision augmentation.

ConcertAI has become a leading player in real-world evidence (RWE) and AI technology for healthcare. What were some of the early challenges you faced in positioning the company as a leader in this space?

You have to be trusted and evolve towards being the reference source. That is earned. The trust comes from your provider partners, believing that the data you are accessing is in the best interests of their patients. Trust comes from your academic and industry partners, who see the evidence of and believe that your data is derived as a perfect reflection of the original patient records and that the concepts you advance are ‘true’ and reflective of current clinical and scientific practice. You also have to achieve a scale that your data solutions represent not only the entire population but also produce conclusions that are confidently generalizable back to the full population being treated with a particular medicine. Technology is similar. Scientists and clinicians are inherently skeptical—as they should be—and don’t trust black boxes or algorithms they don’t understand. So we needed to establish trust there, too, through publications and being open about how our solutions work.

ConcertAI holds the world’s largest oncology and hematology dataset. What unique opportunities does this data create for transforming cancer research and treatment?

I love that question. We are working on this every day! The opportunities to provide value to providers, patients and innovators are almost limitless. In early-phase trials, we are evolving study simulation approaches with digital twins that will change the programs we take into clinical trials. Our data and AI optimizations will lower the time required to go from finalized protocol to finalized submission to regulators by 30 to 40%—meaning new medicines get to patients faster. Our decision augmentation AI solutions will recommend pathways for treatment that are evidence-based and specifically tailored to those pathways, monitor responses in line with the predicted response, and look for potentially beneficial clinical trials when response or benefit is below expectations. Our imaging clinical interpretation solutions operate at the level of operational processes, clinical interpretation, and longer-term view of new interpretations or new interventions that should be considered based on insights and evidence in the future. No longer is an action “once and done” but rather it becomes “once, and then again and again” such that beneficial reassessments and future decisions are an ongoing process! What’s different here is that the view is the entire patient journey—this is a horizontal view versus a series of narrow, deep, vertical views that have to be stitched together. This is an innovation enabled by AI and a profound process change that provides new ways of working to the expert humans involved.

Can you explain how ConcertAI’s Digital Trial Solution works to match cancer patients with life-saving clinical trials? What impact have you seen so far in terms of patient outcomes?

Clinical trials are very complex and require hours of effort by a wide range of highly expert individuals. For most organizations, clinical trials are offered as a responsibility and commitment to patients where the current standard of care may not represent a viable alternative. Trials have not really been very available to patients in community treatment centers, where 80% of patients receive their care. Yet, these are the patients who will ultimately be receiving newly approved medicines. This creates a double dilemma: the majority of patients who need access to trials are limited, and those who are reflective of the ultimate standard of care population are not in the trial dataset. We set a path to resolve these problems.

The results have been great—so positive that we are going to be expanding our number of studies underway by 10x in 2025. We published this for the last American Society of Clinical Oncology meetings and in other areas. Our approach is how we think AI should be implemented—as an augmentation of expert humans where there are large capacity and talent constraints and where lives are at stake. We have developed a set of orchestrated and tuned large language models that access patient records, synthesize characteristics, and match patients to potentially beneficial trials, doing exactly what the expert humans would do—with a fully documented approach to making recommendations and assessments. In the sites where our technologies are deployed, we perform at the level of the most expert humans and accrue patients at 5x or more relative to sites where our technologies are not deployed—the research teams and biopharma innovators are both pleased, and patients benefit most.

How does ConcertAI’s AI-driven approach to trial design and patient recruitment address some of the current limitations in clinical research, such as patient diversity and trial efficiency?

I am proud of my team—they told me three to four years ago that achieving diversity is an obligation and the right thing to do scientifically. They also maintained that it is hard to do if it is manual but requires zero incremental effort if automated. So, we decided then that every dataset and AI SaaS solution would integrate diversity and social determinants of health characteristics as our standard approach. It’s not an option. It’s just what we do. Subsequently, our CARAai™ supported clinical trial design and optimization solutions can assess what ethnic, racial or economic subpopulations may be most adversely impacted by a disease, integrate those considerations into the trial design, ensure that these populations are not unwittingly excluded, and define the clinical sites most likely to assure participation and representativeness. This is where AI can be “AI for Good” and where technology does not introduce a bias but assures that biases don’t enter the process, the ultimate design, or the operational processes around the clinical trial.

What role does ConcertAI play in reducing the burden on healthcare providers and optimizing site selection in clinical trials?

We integrate the work burden into all aspects of our clinical trial solutions. First, there is a burden on the patient. This can be where the site is located, the number of visits required for a study versus the standard of care, or the clinical intensity of a study versus the standard of care, as in the case of additional biopsies. These things can determine whether the patient—or the patient in consultation with their provider—can afford to participate or tolerate and complete participation.

There is also a burden on the provider. If we can automate the identification of patients for clinical trial eligibility, minimize false positives that create work, and provide what we call “AI leverage” to the work of the Clinical Research Associated, Study Nurses, and Physicians, then the burden is lowered. The same is true of our AI Automation Solution, which allows the research team to avoid doing manual data entry—typically 2 to 4 hours at the end of the day, and often completed at home. Early on we looked at the data in the EMR—digital—being manually entered into a portal for the sponsor’s EDC. So digital data is being read and then rekeyed to become digital data again! Here, too, we are using our multi-tuned large language models—this was a real focus of the NVIDIA partnership from the beginning. We are at 55% full automation today, with a very fast path to over 80% in the coming few months. As these elements come together, we’ll get the staff time down to 10% of legacy requirements and make these studies more accessible to more patients.

Precision medicine is a key area where AI is making significant strides. How does ConcertAI’s technology contribute to more precise and personalized cancer treatments?

We’ve not discussed this too much since last year. In December 2023, we assumed responsibility for the American Society of Clinical Oncology’s (ASCO) CancerLinQ program. It is the world’s largest intelligent health network, comprising academic centers, regional hospital systems and community providers. A key part of this network is implementing the ASCO Certified® quality and clinical pathway solutions. Since CancerLinQ is a ConcertAI initiative, we have been growing the network, automating precision oncology pathways, creating new digital twin approaches for augmenting treatment selection for the providers, identifying and messaging critical diagnostic tests that could inform treatment decisions, and doing the same for newly approved medicines that represent another or better treatment alternative. All of this is underpinned by our CARAai™ architecture, again a set of vision LLM and tuned oncology LLMs done in collaboration with NVIDIA. It’s amazing to see the progress being made, and we’re excited about what we’ll be publishing and presenting at next year’s ASCO 2025.

How do you see AI imaging solutions benefiting fields like oncology and radiology, especially as these fields face clinician shortages?

Great question! It is true that both the number of new oncologists and radiologists entering the field is less than the number retiring. However, patient demand is ever-increasing. So, it is the ideal area for providing AI SaaS solutions that support physician and allied care professionals in both workflow optimization and clinical decision augmentation. Radiologists and oncologists will both cite the importance of these new intelligent solutions coming into their fields specifically. Imaging is a wonderful area for AI, and its performance is exceptional. Non-inferiority studies reflect that AI models can be close to or comparable to expert humans in narrow areas. Orchestrated workflows can bring this all together. The same is true in oncology, where we are bringing together molecular test results with immune response data, predictive algorithms for resistance and other elements that will all inform the treatment decision and enable response monitoring. I’ve been in the field for years and on different sides of new innovations—what we can do now is well beyond anything we were ever able to do before, and the pace of change is amazing.

As an experienced leader in healthcare technology, what advice would you offer to new companies looking to make a meaningful impact in healthcare through AI?

You can’t be an AI company without access to data at scale. Data is the substrate for building training and monitoring models. Also, building AI solutions is a team sport. You need domain knowledge at an exceptional depth matched with a new generation of AI model development capabilities that recognizes the behaviors of different classes of AI solutions and can bring them to bear against narrow objectives, specifically tuned for human or above performance. Then, these approaches can be orchestrated in various ways to represent a new system for operating—that is where the changes occur, and the value gets delivered. Practice “AI Humility” as everything is amazing and exhibits things we couldn’t do even six months before. Yet, ‘amazing’ is not necessarily a product or a new way of working—it is just that, technology doing something new. It is the responsibility of the AI company to make it a new way of working and a new approach for delivering an astonishing level of value that was never accessible before. Finally, assume you need to demonstrate trust in business practices, AI models, and solution transparency. We’re still early in our societal journey, and we’re the ones who have to earn the trust to bring about the changes we’re capable of delivering.

Thank you for the great interview, readers who wish to learn more should visit ConcertAI.

[intentmarketresearch-imr]

AI in Pathology Market Grows as Digital Healthcare Advances Globally

Artificial intelligence (AI) is revolutionizing the field of pathology by enhancing diagnostic precision, reducing workload, and improving overall patient outcomes. In 2023, the global AI in pathology market was valued at USD 0.01 billion. With a remarkable projected CAGR of 14.6%, the market is expected to reach USD 0.1 billion by 2030. This explosive growth is attributed to advancements in machine learning (ML), digital pathology systems, and the increasing need for efficient and accurate disease diagnosis.

Key Applications of AI in Pathology

AI is making its mark in pathology by transforming conventional diagnostic processes. Major applications include:

Cancer Diagnosis: AI algorithms analyze large datasets, enabling faster and more accurate cancer detection, grading, and staging. They also help in identifying patterns that might be overlooked by human pathologists.

Workflow Optimization: Automation powered by AI significantly reduces the time required for slide analysis. Tasks such as tissue quantification, cell counting, and lesion detection are streamlined, enhancing laboratory efficiency.

Digital Image Analysis: Advanced image recognition techniques enable AI systems to examine digital slides for abnormalities with exceptional precision. This is especially valuable in resource-limited settings where pathologists might be scarce.

Predictive Analytics: AI can predict disease outcomes and response to treatments by analyzing patient histories and pathology data, aiding in personalized medicine.

Educational Tools: AI-based platforms are being used to train budding pathologists by providing annotated datasets and simulated diagnostic scenarios.

Download Sample Report @ https://intentmarketresearch.com/request-sample/ai-in-pathology-market-3129.html  

Market Drivers

Several factors are driving the rapid growth of the AI in pathology market:

Technological Advancements: The development of deep learning algorithms and high-resolution imaging tools has enhanced AI's diagnostic accuracy and usability.

Growing Disease Burden: The rising prevalence of cancer, neurological disorders, and other chronic diseases necessitates faster and more accurate diagnostics, creating demand for AI-driven pathology solutions.

Shortage of Pathologists: In many parts of the world, there is a significant shortfall of skilled pathologists. AI bridges this gap by augmenting human expertise and handling repetitive tasks effectively.

Integration with Digital Pathology Systems: As digital pathology adoption rises, the seamless integration of AI tools with existing systems is enabling labs to modernize without large-scale overhauls.

Cost Savings: AI helps reduce costs by minimizing errors, improving workflow efficiency, and reducing reliance on human-intensive processes.

Challenges in the AI in Pathology Market

Despite its promising potential, the adoption of AI in pathology faces several challenges:

High Implementation Costs: AI solutions require significant investment in hardware, software, and training, making them inaccessible for smaller labs.

Regulatory Issues: Obtaining approval for AI diagnostic tools involves rigorous regulatory scrutiny, which can delay market entry.

Data Security Concerns: As AI systems rely on patient data, ensuring privacy and compliance with regulations like HIPAA and GDPR remains a critical challenge.

Resistance to Change: The adoption of AI often faces resistance from professionals due to concerns over job security and trust in AI's capabilities.

Opportunities in the AI in Pathology Market

Emerging Markets: Developing nations, with their growing healthcare infrastructure, offer significant opportunities for AI adoption to address pathology workforce shortages.

Integration with Telemedicine: AI-powered pathology systems can complement telemedicine by providing diagnostic services remotely, especially in rural and underserved areas.

Development of Explainable AI: Efforts to improve the transparency of AI decision-making processes will likely boost trust and adoption among healthcare professionals.

Collaborations with Tech Giants: Partnerships between pathology labs and AI technology firms are accelerating the development of innovative diagnostic solutions tailored to specific needs.

Regional Analysis

North America

North America dominates the AI in pathology market, driven by cutting-edge research, strong digital infrastructure, and high healthcare spending. Major players in the region are investing in R&D to develop advanced diagnostic platforms.

Europe

Europe follows closely, with its increasing adoption of digital pathology and AI tools. Supportive regulations and significant public funding in AI research propel market growth in countries like Germany and the UK.

Asia-Pacific

Asia-Pacific is projected to witness the fastest growth due to the region's rising healthcare needs, growing disease burden, and increasing investments in AI-based healthcare solutions. Countries such as China, India, and Japan are emerging as key players in the market.

Latin America, Middle East & Africa

These regions exhibit untapped potential for AI in pathology, with growing awareness about digital healthcare and an increasing focus on building modern diagnostic infrastructure.

Access Full Report @ https://intentmarketresearch.com/latest-reports/ai-in-pathology-market-3129.html 

Key Players in the AI in Pathology Market

Major companies leading the AI in pathology market include:

PathAI

Proscia Inc.

IBM Watson Health

Philips Healthcare

Visiopharm

These companies are at the forefront of developing innovative AI-driven pathology solutions through collaborations, acquisitions, and continuous R&D investments.

Future Prospects and Conclusion

The AI in pathology market is poised for significant transformation over the next decade. By enabling faster, more accurate, and cost-effective diagnostic solutions, AI is addressing key challenges in global healthcare. As technology continues to advance and healthcare systems adopt digital solutions, the AI in pathology market will unlock unparalleled opportunities to revolutionize diagnostics and improve patient outcomes.

About Us

Intent Market Research (IMR) is dedicated to delivering distinctive market insights, focusing on the sustainable and inclusive growth of our clients. We provide in-depth market research reports and consulting services, empowering businesses to make informed, data-driven decisions.

Our market intelligence reports are grounded in factual and relevant insights across various industries, including chemicals & materials, healthcare, food & beverage, automotive & transportation, energy & power, packaging, industrial equipment, building & construction, aerospace & defense, and semiconductor & electronics, among others.

We adopt a highly collaborative approach, partnering closely with clients to drive transformative changes that benefit all stakeholders. With a strong commitment to innovation, we aim to help businesses expand, build sustainable advantages, and create meaningful, positive impacts.

Contact Us

sales@intentmarketresearch.com

US: +1 463-583-2713

[kristinahertzz]

Anatomic Pathology Market

Anatomic Pathology Market Size, Share, Trends: Roche Diagnostics Leads

Digital Pathology and AI Integration Revolutionize Diagnostic Processes

Market Overview: 

The Anatomic Pathology Market is experiencing robust growth from 2024 to 2031. North America currently leads the market, driven by advanced healthcare infrastructure and high adoption rates of innovative diagnostic technologies. Key metrics include increasing prevalence of chronic diseases, rising demand for personalized medicine, and growing investments in healthcare research and development. The market is quickly expanding as a result of the rising prevalence of cancer and other chronic diseases, technical developments in diagnostic procedures, and a greater emphasis on early and accurate disease diagnosis. The integration of digital pathology and artificial intelligence is predicted to drive market expansion by allowing for more efficient and precise pathological assessments.

DOWNLOAD FREE SAMPLE

Market Trends: 

The combination of digital pathology and artificial intelligence (AI) is changing the anatomic pathology landscape. This trend is distinguished by the digitisation of pathology slides and the application of AI algorithms for image analysis, resulting in increased diagnosis accuracy and efficiency. Recent advances in whole slide imaging (WSI) technology have greatly expanded the potential of digital pathology systems, enabling pathologists to view and analyse high-resolution photographs of complete tissue samples. AI-powered image analysis technologies are being used to help pathologists spot minor abnormalities and quantify biomarkers, particularly in oncology applications.

Market Segmentation: 

The Services section of the Anatomic Pathology market, which comprises diagnostic consultation services, is expected to be prominent throughout the forecast period. This segment's growth is primarily driven by the increasing complexity of pathological assessments, rising demand for specialised expertise, and the tendency of smaller healthcare facilities outsourcing pathology services. Recent improvements in the Services category have centred on incorporating modern technology to improve diagnostic skills. Major anatomic pathology service providers are investing in digital pathology platforms and AI-powered diagnostic tools to improve accuracy and efficiency.

Market Key Players: 

Prominent players in the Anatomic Pathology market include Roche Diagnostics, Danaher Corporation, Thermo Fisher Scientific, Hologic, Inc., Agilent Technologies, Becton, Dickinson and Company, PHC Holdings Corporation (Formerly Panasonic Healthcare), Sakura Finetek USA, Inc., Merck KGaA, and Bio SB, Inc. These companies are at the forefront of the industry, continuously innovating and expanding their product portfolios to meet the evolving market demands. Their strategic initiatives and robust distribution networks have enabled them to maintain a strong market presence and drive growth.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[mostlysignssomeportents]

Copyright won't solve creators' Generative AI problem

The media spectacle of generative AI (in which AI companies’ breathless claims of their software’s sorcerous powers are endlessly repeated) has understandably alarmed many creative workers, a group that’s already traumatized by extractive abuse by media and tech companies.

If you’d like an essay-formatted version of this post to read or share, here’s a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2023/02/09/ai-monkeys-paw/#bullied-schoolkids

Even though the claims about “AI” are overblown and overhyped, creators are right to be alarmed. Their bosses would like nothing more than to fire them and replace them with pliable software. The “creative” industries talk a lot about how audiences should be paying for creative works, but the companies that bring creators’ works to market treat their own payments to creators as a cost to be minimized.

Creative labor markets are primarily regulated through copyright: the exclusive rights that accrue to creators at the moment that their works are “fixated.” Media and tech companies then bargain to buy or license those rights. The theory goes that the more expansive those rights are, the more they’ll be worth to corporations, and the more they’ll pay creators for them.

That’s the theory. In practice, we’ve spent 40 years expanding copyright. We’ve made it last longer; expanded it to cover more works, hiked the statutory damages for infringements and made it easier to prove violations. This has made the entertainment industry larger and more profitable — but the share of those profits going to creators has declined, both in real terms and proportionately.

In other words, today creators have more copyright, the companies that buy creators’ copyrights have more profits, but creators are poorer than they were 40 years ago. How can this be so?

As Rebecca Giblin and I explain in our book Chokepoint Capitalism, the sums creators get from media and tech companies aren’t determined by how durable or far-reaching copyright is — rather, they’re determined by the structure of the creative market.

https://chokepointcapitalism.com/

The market is concentrated into monopolies. We have five big publishers, four big studios, three big labels, two big ad-tech companies, and one gargantuan ebook/audiobook company. The internet has been degraded into “five giant websites, each filled with screenshots from the other four”:

https://twitter.com/tveastman/status/1069674780826071040

Under these conditions, giving a creator more copyright is like giving a bullied schoolkid extra lunch money. It doesn’t matter how much lunch money you give that kid — the bullies will take it all, and the kid will still go hungry (that’s still true even if the bullies spend some of that stolen lunch money on a PR campaign urging us all to think of the hungry children and give them even more lunch money):

https://doctorow.medium.com/what-is-chokepoint-capitalism-b885c4cb2719

But creative workers have been conditioned — by big media and tech companies — to reflexively turn to copyright as the cure-all for every pathology, and, predictably, there are loud, insistent calls (and a growing list of high-profile lawsuits) arguing that training a machine-learning system is a copyright infringement.

This is a bad theory. First, it’s bad as a matter of copyright law. Fundamentally, machine learning systems ingest a lot of works, analyze them, find statistical correlations between them, and then use those to make new works. It’s a math-heavy version of what every creator does: analyze how the works they admire are made, so they can make their own new works.

If you go through the pages of an art-book analyzing the color schemes or ratios of noses to foreheads in paintings you like, you are not infringing copyright. We should not create a new right to decide who is allowed to think hard about your creative works and learn from them — such a right would make it impossible for the next generation of creators to (lawfully) learn their craft:

https://www.oblomovka.com/wp/2022/12/12/on-stable-diffusion/

(Sometimes, ML systems will plagiarize their own training data; that could be copyright infringement; but a) ML systems will doubtless get guardrails that block this plagiarism; and, b) even after that happens, creators will still worry about being displaced by ML systems trained on their works.)

We should learn from our recent history here. When sampling became a part of commercial hiphop music, some creators clamored for the right to control who could sample their work and to get paid when that happened. The musicians who sampled argued that inserting a few bars from a recording was akin to a jazz trumpeter who works a few bars of a popular song into a solo. They lost that argument, and today, anyone who wants to release a song commercially will be required — by radio stations, labels, and distributors — the clear that sample.

This change didn’t make musicians better off. The Big Three labels — Sony, Warners, and Universal, who control 70% of the world’s recorded music — now require musicians to sign away the rights to samples from their works. The labels also refuse to sell sampling licenses to musicians unless they are signed to one of the Big Three.

Thus, producing music with a sample requires that you take whatever terms the Big Three impose on you, including giving up the right to control sampling of your music. We gave the schoolkids more lunch money and the bullies took that, too.

https://locusmag.com/2020/03/cory-doctorow-a-lever-without-a-fulcrum-is-just-a-stick/

The monopolists who control the creative industries are already getting ahead of the curve on this one. Companies that hire voice actors are requiring those actors to sign away the (as yet nonexistant) right to train a machine-learning model with their voices:

https://www.vice.com/en/article/5d37za/voice-actors-sign-away-rights-to-artificial-intelligence

The National Association of Voice Actors is (quite rightly) advising its members not to sign contracts that make this outrageous demand, and they note that union actors are having success getting these clauses struck, even retroactively:

https://navavoices.org/synth-ai/

That’s not surprising — labor unions have a much better track record of getting artists’ paid than giving creators copyright and expecting them to bargain individually for the best deal they can get. But for non-union creators — the majority of us — getting this language struck is going to be a lot harder. Indeed, we already sign contracts full of absurd, unconscionable nonsense that our publishers, labels and studios refuse to negotiate:

https://doctorow.medium.com/reasonable-agreement-ea8600a89ed7

Some of the loudest calls for exclusive rights over ML training are coming not from workers, but from media and tech companies. We creative workers can’t afford to let corporations create this right — and not just because they will use it against us. These corporations also have a track record of creating new exclusive rights that bite them in the ass.

For decades, media companies stretched copyright to cover works that were similar to existing works, trying to merge the idea of “inspired by” and “copied from,” assuming that they would be the ones preventing others from making “similar” new works.

But they failed to anticipate the (utterly predictable) rise of copyright trolls, who launched a string of lawsuits arguing that popular songs copied tiny phrases (or just the “feel”) of their clients’ songs. Pharrell Williams and Robin Thicke’s got sued into radioactive rubble by Marvin Gaye’s estate over their song “Blurred Lines” — which didn’t copy any of Gaye’s words or melodies, but rather, took its “feel”:

https://www.rollingstone.com/music/music-news/robin-thicke-pharrell-lose-multi-million-dollar-blurred-lines-lawsuit-35975/

Today, every successful musician lives in dread of a multi-million-dollar lawsuit over incidental similarities to obscure tracks. Last spring, Ed Sheeran beat such a suit, but it was a hollow victory. As Sheeran said, with 60,000 new tracks being uploaded to Spotify every day, these similarities are inevitable:

https://twitter.com/edsheeran/status/1511631955238047751

The major labels are worried about this problem, too — but they are at a loss as to what to do about it. They are completely wedded to the idea that every part of music should be converted to property, so that they can expropriate it from creators and add it to their own bulging portfolios. Like a monkey trapped because it has reached through a hole into a hollow log to grab a banana that won’t fit back through the hole, the labels can’t bring themselves to let go.

https://pluralistic.net/2022/04/08/oh-why/#two-notes-and-running

That’s the curse of the monkey’s paw: the entertainment giants argued for everything to be converted to a tradeable exclusive right — and now the industry is being threatened by trolls and ML creeps who are bent on acquiring their own vast troves of pseudo-property.

There’s a better way. As NAVA president Tim Friedlander told Motherboard’s Joseph Cox, “NAVA is not anti-synthetic voices or anti-AI, we are pro voice actor. We want to ensure that voice actors are actively and equally involved in the evolution of our industry and don’t lose their agency or ability to be compensated fairly for their work and talent.”

This is as good a distillation of the true Luddite ethic as you could ask for. After all, the Luddites didn’t oppose textile automation: rather, they wanted a stake in its rollout and a fair share of its dividends:

https://locusmag.com/2022/01/cory-doctorow-science-fiction-is-a-luddite-literature/

Turning every part of the creative process into “IP” hasn’t made creators better off. All that’s it’s accomplished is to make it harder to create without taking terms from a giant corporation, whose terms inevitably include forcing you to trade all your IP away to them. That’s something that Spider Robinson prophesied in his Hugo-winning 1982 story, “Melancholy Elephants”:

http://www.spiderrobinson.com/melancholyelephants.html

This week (Feb 8–17), I’ll be in Australia, touring my book Chokepoint Capitalism with my co-author, Rebecca Giblin. We’re doing a remote event for NZ on Feb 13. Next are Melbourne (Feb 14), Sydney (Feb 15) and Canberra (Feb 16/17). I hope to see you!

Image: Cryteria (modified) https://commons.wikimedia.org/wiki/File:HAL9000.svg

CC BY 3.0 https://creativecommons.org/licenses/by/3.0/deed.en

[Image ID: A poster for the 1933 movie ‘The Monkey’s Paw.’ The fainting ingenue has been replaced by the glaring red eye of HAL9000 from 2001: A Space Odyssey.]

[govindtbrc]

Pathology Laboratories Market: Advancements in Diagnostic Services and Technology up to 2033

Market Definition The Pathology Laboratories Market encompasses healthcare facilities dedicated to diagnosing diseases through the examination of patient samples such as blood, urine, tissues, and other body fluids. These labs utilize advanced diagnostic technologies, including molecular, genetic, and biochemical tests, to provide critical insights for the detection, prevention, and treatment of various conditions. Pathology laboratories serve as a vital component in the healthcare continuum, supporting doctors and clinicians with evidence-based diagnoses and therapeutic decisions.

To Know More @ https://www.globalinsightservices.com/reports/pathology-laboratories-market

The global pathology laboratories market is set to expand from $49.8 billion in 2023 to $97.5 billion by 2033, with a robust CAGR of 7.0%.

Market Outlook The Pathology Laboratories Market is witnessing robust growth, driven by rising demand for accurate and timely diagnostic services. With an increasing global burden of chronic diseases like cancer, diabetes, and cardiovascular conditions, there is a heightened need for sophisticated diagnostic tools that can provide early and precise detection. Furthermore, the emergence of personalized medicine and the advancement in diagnostic technologies are transforming the landscape of pathology laboratories, making them indispensable in modern medical practice.

One of the key trends reshaping the market is the integration of artificial intelligence (AI) and machine learning (ML) into pathology. These technologies are being used to enhance the accuracy and efficiency of diagnostic processes, from image analysis to data interpretation. AI-powered solutions help pathologists analyze large datasets rapidly, reducing the likelihood of human error and enabling faster reporting times. As a result, pathology laboratories are becoming more efficient, which is crucial for managing the increasing volume of patient samples.

The shift towards digital pathology is another significant trend impacting the market. By digitizing slides and using digital tools for analysis and storage, pathology labs can streamline workflows, facilitate remote consultations, and improve collaboration among healthcare professionals. Digital pathology is particularly beneficial in the current era of telemedicine and remote healthcare, allowing for continuity of care even when in-person consultations are not possible.

The market is also being shaped by advancements in molecular and genetic testing. With the growing understanding of the genetic basis of diseases, there is a rising demand for pathology services that can provide genetic and genomic analyses. These tests are essential for the diagnosis of complex diseases, such as various types of cancer, and for tailoring treatments to individual patients’ genetic profiles. Consequently, pathology laboratories are investing heavily in next-generation sequencing (NGS) technologies and other cutting-edge diagnostic tools.

An increasing focus on preventive healthcare is another factor contributing to the market’s growth. Governments and healthcare organizations worldwide are emphasizing early disease detection and preventive measures, driving demand for routine pathology tests and screenings. Additionally, the expansion of healthcare infrastructure in developing regions is opening new opportunities for pathology service providers, with governments investing in the establishment of diagnostic centers to meet the needs of growing populations.

Request the sample copy of report @ https://www.globalinsightservices.com/request-sample/GIS32441

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request For Report Customization @ https://www.globalinsightservices.com/request-customization/GIS32441

Market Segmentation

In 2023, the pathology laboratories market exhibited a robust volume, with a projection to grow substantially over the next decade. The clinical pathology segment dominates the market with a 55% share, driven by its extensive application in disease diagnosis and management. Anatomical pathology follows with a 30% share, reflecting its critical role in cancer diagnostics. The molecular pathology segment, although smaller at 15%, is rapidly expanding due to advances in genetic testing and personalized medicine. This growth trajectory is supported by increasing healthcare expenditure and technological advancements in diagnostic tools.

The competitive landscape is characterized by key players such as Quest Diagnostics, LabCorp, and Sonic Healthcare, who are leveraging strategic partnerships and acquisitions to enhance their market positions. Regulatory frameworks, particularly those established by the FDA and European Medicines Agency, significantly impact market dynamics by setting compliance standards that drive innovation and quality. Future projections indicate a promising outlook, with a 10% annual growth rate anticipated, fueled by rising demand for early disease detection and precision medicine. The integration of artificial intelligence and machine learning in diagnostic processes is expected to further revolutionize the market, offering enhanced accuracy and efficiency in pathology services.

Major Players

Sonic Healthcare

Eurofins Scientific

Quest Diagnostics

Laboratory Corporation of America

Unilabs

BioReference Laboratories

ARUP Laboratories

Synlab

Cerba Healthcare

ACM Global Laboratories

Genomic Health

PathGroup

Clinical Reference Laboratory

Labco

MedLabs Diagnostics

KingMed Diagnostics

Al Borg Medical Laboratories

Metropolis Healthcare

InVitro

Amedes

Request For Discounted Pricing @ https://www.globalinsightservices.com/request-special-pricing/GIS32441

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis

For In-Depth Competitive Analysis, Buy Now @ https://www.globalinsightservices.com/checkout/single_user/GIS32441

About Us

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[stevecarell600]

Cancer Diagnostics Market Size, Share, Industry Growth and Emerging Trends Analysis by 2032

In 2023, the global cancer diagnostics market was worth $15.13 billion. It's expected to grow steadily, reaching $16.12 billion in 2024 and climbing to $31 billion by 2032, with an average annual growth rate of 8.5% over this period. North America led the market in 2023, holding a significant 35.89% share. 

Informational Source:

Major Key Companies Covered in Cancer Diagnostics Market are:

F. Hoffmann-La Roche Ltd (Switzerland)

Thermo Fisher Scientific Inc. (U.S.)

Abbott (U.S.)

Illumina, Inc. (U.S.)

GE Healthcare (U.S.)

BD (U.S.)

bioMérieux SA (France)

Myriad Genetics, Inc (U.S.)

Bio-Rad Laboratories, Inc. (U.S.)

QIAGEN (Germany)

Advancements and Trends in Cancer Diagnostics

Cancer diagnostics play a critical role in detecting, monitoring, and managing cancer at various stages. With advancements in technology and ongoing research, the field has witnessed transformative changes, offering new hope for early detection and improved patient outcomes. Below, we delve into the latest innovations and trends shaping cancer diagnostics today.

1. The Role of Liquid Biopsies

Liquid biopsy technology has revolutionized cancer diagnostics by offering a non-invasive method to detect cancer-related biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, in blood or other bodily fluids. Unlike traditional biopsies, liquid biopsies can be performed with minimal discomfort and provide real-time insights into tumor dynamics.

Key Applications:

Early Detection: Screening for cancers like lung, colorectal, and breast cancers before symptoms appear.

Monitoring: Tracking tumor progression and response to treatments.

Personalized Treatment: Identifying genetic mutations to guide targeted therapies.

Recent Innovations:

Multi-Cancer Early Detection (MCED): Tests like GRAIL’s Galleri aim to detect multiple cancers simultaneously by analyzing ctDNA.

High Sensitivity Platforms: Techniques like next-generation sequencing (NGS) enhance the precision of biomarker detection.

2. Artificial Intelligence (AI) in Cancer Diagnostics

AI and machine learning (ML) are increasingly being integrated into cancer diagnostics to analyze vast amounts of data, identify patterns, and improve diagnostic accuracy. These technologies augment traditional methods by reducing human error and speeding up the diagnostic process.

Applications:

Image Analysis: AI algorithms analyze imaging data from MRI, CT, and mammography to detect anomalies indicative of cancer.

Pathology: Digital pathology solutions powered by AI can evaluate tissue samples for malignant changes with high precision.

Risk Prediction Models: AI systems can predict a patient’s risk of developing cancer based on their medical history, genetics, and lifestyle factors.

Notable Examples:

Google Health’s AI: Demonstrated higher accuracy than human radiologists in detecting breast cancer in mammograms.

PathAI: Utilizes deep learning to assist pathologists in diagnosing cancer from biopsy samples.

3. Advances in Molecular Diagnostics

Molecular diagnostics has seen significant advancements, allowing for the precise identification of genetic and molecular markers associated with different cancer types.

Technologies Driving Innovation:

Next-Generation Sequencing (NGS): Enables comprehensive genomic profiling to identify mutations, fusions, and other alterations that drive cancer.

Polymerase Chain Reaction (PCR): Used to amplify and detect specific DNA or RNA sequences linked to cancer.

CRISPR-based Detection: CRISPR technology is being developed for rapid and highly specific cancer biomarker detection.

Impact on Personalized Medicine:

Molecular diagnostics forms the backbone of personalized medicine by guiding therapies tailored to the genetic profile of a patient’s tumor. For instance:

EGFR mutations in lung cancer guide the use of tyrosine kinase inhibitors.

BRCA mutations in breast and ovarian cancer inform the use of PARP inhibitors.

4. Imaging Technologies in Cancer Detection

Imaging remains a cornerstone of cancer diagnostics, and advancements in this field have significantly improved the ability to detect and monitor tumors.

Innovations in Imaging:

Positron Emission Tomography (PET): Combined with CT or MRI, PET scans provide detailed information about tumor metabolism and structure.

Multiparametric MRI (mpMRI): Offers a more accurate assessment of prostate cancer compared to traditional methods.

AI-Enhanced Imaging: Machine learning algorithms improve the resolution and interpretation of imaging data, aiding in early detection and reducing false positives.

Emerging Modalities:

Optical Imaging: Techniques like fluorescence and bioluminescence imaging allow for the visualization of cancer at the cellular level.

Theranostic Imaging: Combines diagnostic imaging with therapy, enabling real-time monitoring of treatment efficacy.

5. Biomarker Discovery and Utilization

Biomarkers are critical for early detection, diagnosis, and prognosis in cancer care. Advances in proteomics, genomics, and metabolomics have expanded the pool of potential biomarkers.

Breakthroughs in Biomarker Research:

Proteomics: Identifying protein signatures unique to cancer cells.

Epigenetics: Analyzing DNA methylation and histone modifications as cancer-specific markers.

Metabolomics: Profiling metabolic changes associated with cancer progression.

Clinical Utility:

Predictive Biomarkers: EGFR, HER2, and PD-L1 guide targeted and immunotherapies.

Prognostic Biomarkers: Help estimate disease progression and survival rates.

Companion Diagnostics: Ensure that patients receive the most effective therapy based on their biomarker profile.

6. Point-of-Care (POC) Diagnostics

Point-of-care testing is transforming cancer diagnostics by bringing testing capabilities closer to patients, reducing the time to diagnosis and enabling quicker interventions.

Examples of POC Diagnostics:

Portable Devices: Handheld devices for detecting specific biomarkers in blood or saliva.

Lab-on-a-Chip Technology: Integrates multiple diagnostic processes on a microchip for rapid results.

Immunoassays: Quick tests for detecting cancer antigens, such as PSA for prostate cancer.

Impact on Low-Resource Settings:

POC diagnostics are particularly valuable in remote or underserved areas, where access to advanced diagnostic facilities may be limited.

7. Role of Genomics and Epigenomics

Genomic and epigenomic approaches are uncovering the complexities of cancer, enabling highly personalized diagnostic and therapeutic strategies.

Key Areas of Progress:

Whole Genome Sequencing (WGS): Offers a complete view of genetic alterations driving cancer.

Epigenetic Markers: Identifying changes in gene expression regulation without altering DNA sequences.

RNA Sequencing: Provides insights into gene expression changes specific to cancer.

Implications for Clinical Practice:

These techniques are helping identify rare and aggressive cancers, paving the way for novel treatments and clinical trials.

8. Emerging Diagnostic Technologies

Several groundbreaking technologies are poised to redefine cancer diagnostics in the coming years:

Nanotechnology:

Nanoparticles: Used for targeted imaging and detection of cancer cells.

Nanosensors: Detect minute changes in biomarker levels with high sensitivity.

Single-Cell Analysis:

Examines individual cancer cells, providing insights into tumor heterogeneity and resistance mechanisms.

Microbiome Analysis:

Studies suggest that changes in the gut microbiome may be linked to cancer development, offering a new avenue for diagnostics.

9. Challenges and Future Directions

Despite significant progress, challenges remain in the widespread adoption and implementation of advanced cancer diagnostics.

Key Challenges:

Cost: Many advanced diagnostic tools are expensive and inaccessible to a large population.

Regulatory Hurdles: Approvals for new diagnostics can be lengthy and complex.

Integration: Combining diverse diagnostic data into a cohesive patient profile.

Future Focus Areas:

Affordable Solutions: Development of cost-effective diagnostic tools for global accessibility.

Precision Diagnostics: Further integration of genomics, proteomics, and AI for more accurate and personalized care.

Global Collaboration: Sharing data and resources to accelerate innovation and standardize best practices.

Conclusion

The field of cancer diagnostics is undergoing a transformative era, fueled by technological innovations and a deeper understanding of cancer biology. From liquid biopsies and AI-driven imaging to molecular diagnostics and epigenomics, these advancements are paving the way for earlier detection, improved accuracy, and personalized treatment.

[psychicsheeparcade]

Immunohistochemistry Market Share, Size, Demand, Key Players by Forecast 2034

The Immunohistochemistry (IHC) market is a rapidly growing segment in the field of life sciences, driven by advancements in diagnostic techniques, increasing prevalence of chronic diseases, and rising demand for personalized medicine. IHC is a technique used to detect specific antigens in tissue samples by employing antibodies, enabling researchers and clinicians to gain insights into disease mechanisms, tumor classification, and therapeutic targets.

The global immunohistochemistry market is expected to reach USD 7.95 billion in 2034 based on average growth. Additionally, the analysis projects that between 2024 and 2034, the market would expand at a compound annual growth rate (CAGR) of 7.5%. It is projected that the worldwide immunohistochemistry industry would bring in USD 3.68 billion by 2024. 

Get a Sample Copy of Report, Click Here@  https://wemarketresearch.com/reports/request-free-sample-pdf/immunohistochemistry-market/1595

Immunohistochemistry Market Drivers

Rising Incidence of Cancer: IHC plays a pivotal role in cancer diagnosis and prognosis by providing insights into tumor origin and progression. The increasing prevalence of cancer globally is a significant driver for the market.

Advancements in Diagnostic Techniques: Technological advancements, such as automated staining systems and digital pathology, have improved the accuracy and efficiency of IHC, making it a preferred diagnostic tool.

Growth in Personalized Medicine: IHC is extensively used to determine biomarker expression levels, aiding in targeted therapies and personalized treatment plans.

Expansion of Healthcare Infrastructure: Emerging markets are witnessing significant investments in healthcare infrastructure, leading to greater adoption of advanced diagnostic tools like IHC.

Immunohistochemistry  Market Challenges

High Costs of IHC Instruments and Reagents: The cost of setting up IHC labs and procuring antibodies and reagents can be prohibitive, especially for smaller healthcare facilities.

Limited Skilled Workforce: Performing IHC tests requires expertise, and the shortage of trained professionals can hinder market growth.

Immunohistochemistry Market Opportunities

Growth in Emerging Markets: Developing countries in Asia-Pacific and Latin America are investing heavily in healthcare, creating lucrative opportunities for IHC manufacturers.

Integration with Artificial Intelligence (AI): AI-powered image analysis tools are being integrated with IHC to enhance diagnostic precision and reduce human error.

Emerging Trends in the IHC Market

Multiplex Immunohistochemistry (mIHC):

Enables simultaneous detection of multiple biomarkers within a single tissue sample, offering deeper insights into complex diseases like cancer and immune disorders.

Growing demand in immuno-oncology research and drug development.

Integration of Digital Pathology:

Adoption of whole-slide imaging and AI-powered diagnostic solutions to enhance workflow efficiency and diagnostic accuracy.

Facilitates remote consultations and second opinions through telepathology.

Companion Diagnostics:

Growing use of IHC in companion diagnostics to identify patients likely to benefit from specific therapies, particularly in oncology.

Examples include HER2 testing in breast cancer and PD-L1 testing in immunotherapy.

Automated Systems and Robotics:

Increasing use of automated staining platforms for faster processing and reduced manual errors.

Innovations like on-board reagent management systems to enhance lab productivity.

Emergence of Novel Biomarkers:

Identification of new biomarkers for complex diseases, expanding the scope of IHC applications.

Significant focus on immune checkpoint biomarkers such as CTLA-4 and LAG-3.

Immunohistochemistry Key  Market Players 

The Immunohistochemistry Market is dominated by a few large companies, such as

F. Hoffmann-La Roche Ltd

Agilent Technologies, Inc.

Danaher Corporation (Leica Biosystems)

Thermo Fisher Scientific Inc.

Merck KGaA (MilliporeSigma)

Bio-Rad Laboratories, Inc.

Abcam plc

Biocare Medical, LLC

Cell Signaling Technology, Inc. (CST)

PerkinElmer Inc.

Sakura Finetek Japan Co., Ltd.

Becton, Dickinson and Company (BD)

Immunohistochemistry Market Segments

By Product

Antibodies

Kits

REAGENTS

By End-User

Hospitals

Academic

Diagnostic Labs

By Application

Forensic

Diagnostic

Research

Immunohistochemistry Industry: Regional Analysis

 North American market's forecast

North America was the largest market in the world in 2023, with more than 38% of the worldwide market. The region's supremacy is attributed to a number of factors, including a stable healthcare system, the presence of significant market participants, a strong emphasis on cancer research and individualized treatment, and the widespread use of state-of-the-art diagnostic techniques. The United States and Canada are the two countries that provide the largest contributions to this industry.  

Asia-Pacific Market Forecasts

Increased investment in healthcare infrastructure, a growing demand for individualized care, and growing awareness of early cancer detection are the primary drivers of growth in this field. The leading contributors to the regional market are South Korea, Japan, India, and China. The huge patient base and the increasing number of pharmaceutical and biotechnology companies in this sector present numerous opportunities for market growth.    

Market Statistics for Europe

The market is growing in this sector due to a number of factors, including rising healthcare expenses, the incidence of chronic illnesses, and a strong focus on research and development in nations like the UK, France, and Germany. Favorable reimbursement and regulatory environments also contribute to the growth of the European IHC market.  

FAQs on the Immunohistochemistry (IHC) Market

1. What is Immunohistochemistry (IHC)?

2. What are the primary applications of IHC?

3. Why is IHC important in cancer diagnosis?

4. What are the main products used in IHC?

5. What are the latest advancements in the IHC market

[mordorintelligencemarketresearch]

The Ultrasound Industry: Trends, Growth, and Market Insights

Ultrasound Market Overview:

The global ultrasound market was valued at approximately USD 7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6-7% from 2023 to 2030, reaching over USD 11 billion by 2030. The increasing adoption of ultrasound technology across various healthcare applications, the rise in chronic diseases, and the growing demand for point-of-care diagnostic tools are some of the key factors fueling this market’s growth.

Ultrasound devices are used in diagnostic imaging for visualizing internal organs, tissues, and blood flow. The technology relies on high-frequency sound waves to create real-time images of the body. Its non-invasive nature and the absence of ionizing radiation make it an attractive alternative to other imaging methods, such as X-rays and CT scans.

Key Market Trends:

Portable and Handheld Ultrasound Devices:

Advancements in ultrasound technology have led to the development of portable and handheld ultrasound devices. These compact, easy-to-use devices are particularly popular in emergency care settings, remote clinics, and for point-of-care diagnostics. They provide the flexibility of bedside imaging, enabling healthcare providers to perform quick assessments without the need for a traditional ultrasound machine.

The development of handheld devices that can connect to smartphones and tablets via apps is further revolutionizing the market. These devices not only improve accessibility but also reduce the overall cost of ultrasound services, making them a valuable tool in both developed and emerging markets.

Increasing Demand for Point-of-Care Ultrasound (POCUS):

Point-of-care ultrasound (POCUS) refers to ultrasound devices used at the patient’s bedside or at the point of care for immediate diagnosis and treatment. This technology is growing in popularity due to its ability to provide rapid, real-time imaging, aiding in critical decision-making during emergencies and in fast-paced settings like trauma care, intensive care units (ICUs), and emergency departments.

POCUS devices are especially valuable in rural and underserved areas where access to advanced imaging centers may be limited. The portability and affordability of these devices allow for faster diagnosis and reduced patient wait times, improving outcomes and patient satisfaction.

Technological Advancements in Imaging Quality:

Technological innovations in ultrasound technology have significantly improved the quality of imaging. 3D and 4D ultrasound systems, which provide more detailed and accurate images than traditional 2D systems, are becoming increasingly common, especially in obstetrics and gynecology for fetal imaging.

The integration of artificial intelligence (AI) into ultrasound systems is also enhancing diagnostic capabilities. AI algorithms can assist in identifying pathologies, such as tumors or abnormalities, more accurately and faster than human operators alone. The use of AI-powered ultrasound systems is expected to grow significantly, contributing to better diagnostic precision and reduced human error.

Growth in Obstetrics and Gynecology Applications:

Ultrasound remains the gold standard in obstetric imaging, used for monitoring fetal development during pregnancy. 2D, 3D, and 4D ultrasound technologies allow doctors to track fetal growth, detect abnormalities, and assess the health of both mother and child. The rising demand for prenatal care and minimally invasive procedures is driving growth in the obstetric ultrasound market.

In gynecology, ultrasound is used to diagnose conditions like fibroids, ovarian cysts, and endometriosis, contributing to an increase in outpatient ultrasound procedures.

Rising Adoption in Cardiology:

In cardiology, echocardiograms (ultrasound of the heart) are commonly used to assess heart function, detect heart disease, and guide treatment plans. Ultrasound imaging provides real-time feedback on blood flow, heart valve function, and overall cardiac health. The growing prevalence of cardiovascular diseases (CVDs) is driving the demand for echocardiography and ultrasound-based cardiovascular diagnostics.

In addition, the growing adoption of cardiac imaging modalities such as strain imaging, contrast-enhanced ultrasound, and fusion imaging techniques is further boosting the ultrasound market in the cardiology segment.

Growth in Emerging Markets:

As healthcare access improves globally, particularly in developing countries, the demand for affordable and accessible imaging tools like ultrasound is on the rise. Ultrasound is seen as a cost-effective, non-invasive alternative to more expensive diagnostic methods like CT and MRI scans. Additionally, as global healthcare spending increases, particularly in emerging markets such as India, China, and Africa, the demand for ultrasound devices is expected to grow, providing new market opportunities.

Market Segmentation:

The ultrasound market can be segmented based on technology, application, end-user, and region:

By Technology:

2D Ultrasound: The traditional form of ultrasound, used for general diagnostics.

3D/4D Ultrasound: Provides more detailed images, often used in obstetrics and gynecology.

Doppler Ultrasound: Used to assess blood flow and detect blockages in blood vessels.

High-frequency Ultrasound: Typically used for imaging small organs and tissues.

By Application:

Obstetrics and Gynecology: Fetal imaging, monitoring maternal health.

Cardiology: Echocardiography for heart health.

Musculoskeletal Imaging: Diagnosing conditions like tendinitis, fractures, and joint issues.

Abdominal Imaging: Detecting conditions like liver disease, kidney stones, and gallbladder issues.

Urology: Diagnosing conditions in the urinary system, such as bladder issues or kidney stones.

Other Applications: Including vascular, dermatology, and ophthalmology.

By End-User:

Hospitals: The largest segment, where most diagnostic imaging procedures are carried out.

Clinics and Outpatient Centers: Increasing demand for ultrasound in private practices and clinics.

Diagnostic Imaging Centers: Specialized centers offering imaging services.

Others: Including research institutions and homecare settings.

By Region:

North America: Leading the market due to advanced healthcare infrastructure, high adoption of new technologies, and a strong emphasis on healthcare spending.

Europe: Growth driven by government investment in healthcare and the rising prevalence of chronic diseases.

Asia-Pacific: A rapidly growing market, with increased healthcare access, particularly in India and China.

Rest of the World: Significant growth in Latin America, the Middle East, and Africa due to improved healthcare accessibility.

Growth Drivers:

Rising Prevalence of Chronic Diseases: The global increase in chronic diseases such as cardiovascular disease, diabetes, and cancer is contributing to the growing need for diagnostic imaging, including ultrasound. Ultrasound plays a key role in diagnosing and monitoring the progression of these diseases.

Aging Population: As the global population ages, the demand for diagnostic services, including ultrasound, is expected to increase. Older adults are more likely to develop chronic conditions that require ongoing monitoring and diagnostic imaging.

Technological Advancements: Innovations in ultrasound technology, including the development of portable devices, AI integration, and enhanced imaging capabilities, are driving the demand for more advanced ultrasound systems. These innovations make ultrasound more accessible and improve diagnostic accuracy.

Increased Focus on Minimally Invasive Procedures: Ultrasound is often used in minimally invasive procedures, including guided biopsies and injections. The growing preference for non-invasive or minimally invasive procedures is driving the adoption of ultrasound as a tool for such interventions.

Challenges Facing the Market:

High Equipment Costs: Despite being more affordable than other imaging technologies like MRI and CT, ultrasound devices can still be expensive, particularly high-end models with advanced features such as 3D/4D imaging or AI integration. This can limit their accessibility, especially in low-resource settings.

Technician Skill and Training: The quality of ultrasound imaging is heavily dependent on the skill and experience of the technician performing the procedure. Proper training and certification are essential to ensure accurate diagnostics, which can be a challenge in certain regions.

Regulatory Hurdles: The ultrasound industry faces regulatory challenges, as devices must meet stringent safety and performance standards before they can be marketed. Regulatory approvals can take time and increase the cost of bringing new technologies to market.

Key Players in the Ultrasound Market:

General Electric (GE) Healthcare: A leading provider of ultrasound imaging equipment with a wide range of products for different healthcare applications.

Siemens Healthineers: Known for its high-end ultrasound systems, including advanced imaging technologies and portable ultrasound devices.

Philips Healthcare: Offers a broad portfolio of ultrasound solutions, with a strong focus on improving clinical outcomes through advanced imaging and AI-powered solutions.

Canon Medical Systems: Provides a variety of ultrasound systems for different diagnostic applications, with a focus on high-quality imaging.

Hitachi Medical Systems: A major player in the ultrasound market, offering both conventional and portable ultrasound solutions.

Market Outlook:

The ultrasound industry is on a growth trajectory, driven by technological advancements, increasing healthcare needs, and rising adoption of non-invasive imaging methods. With continuous innovation in imaging capabilities, the demand for portable devices, and a focus on more accurate and faster diagnostics, the ultrasound market is poised to reach new heights. However, challenges such as high equipment costs and training requirements need to be addressed to maximize the potential of this technology. Overall, ultrasound will continue to be a cornerstone of modern diagnostic imaging and patient care.

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence